caa a22 4500 605491089 CHVBK 20210128100508.0 cr unu---uuuuu 210128e20150601xx s 000 0 eng 10.1007/s10147-014-0726-y doi (NATIONALLICENCE)springer-10.1007/s10147-014-0726-y Feasibility and efficacy of induction docetaxel, cisplatin, and 5-fluorouracil chemotherapy combined with concurrent weekly cisplatin chemoradiotherapy for locally advanced head and neck squamous cell carcinoma [Elektronische Daten] [Takatsugu Mizumachi, Akihiro Homma, Tomohiko Kakizaki, Tomohiro Sakashita, Satoshi Kano, Hiromitsu Hatakeyama, Kazuhiko Tsuchiya, Koichi Yasuda, Rikiya Onimaru, Hiroki Shirato, Jun Taguchi, Yasushi Shimizu, Ichiro Kinoshita, Hirotoshi Akita, Satoshi Fukuda] Abstract : Background: The aim of this study was to evaluate the feasibility of induction docetaxel, cisplatin, and 5-fluorouracil chemotherapy followed by concurrent weekly cisplatin chemoradiotherapy for patients with locally advanced head and neck squamous cell carcinoma (HNSCC). Methods: Between 2010 and 2013, 30 patients with Stage IV HNSCC were treated in Hokkaido University Hospital with three cycles of induction chemotherapy (docetaxel 75mg/m2 and cisplatin 75mg/m2, day 1; and 5-fluorouracil 750mg/m2/day 120h continuous infusion, every 3weeks) followed by concurrent weekly cisplatin (40mg/m2, on weeks 1, 2, 3, 5, 6 and 7) chemoradiotherapy. Results: Three courses of induction chemotherapy were performed in 25 patients (83%) with grade 3-4 toxicities during induction chemotherapy observed in 22 patients (73%). The major toxicities were hematologic, with 22 cases (73%) showing grade 3-4 neutropenia. Radiotherapy was completed (70Gy) in 29 patients (97%), while a total of 19 patients (63%) completed five (13 patients) or six (6 patients) courses of chemotherapy. During concurrent chemoradiotherapy, no grade 4 hematological toxicities were observed. Grade 4 dermatitis was observed in one patient, and grade 3 mucositis was observed in 12 patients. There were no treatment-related deaths during the induction chemotherapy or concurrent chemoradiotherapy. The 1- and 2-year progression-free survival rates and the 1- and 2-year overall survival rates were 86%, 72%, and 89%, 81%, respectively. Conclusion: Sequential therapy composed of induction chemotherapy followed by concurrent weekly cisplatin chemoradiotherapy is feasible, showing encouraging results in patients with locally advanced HNSCC. Concurrent weekly cisplatin chemoradiotherapy following induction chemotherapy appears to be a suitable alternative to three-weekly high-dose cisplatin therapy. Japan Society of Clinical Oncology, 2014 Head and neck cancer nationallicence Induction chemotherapy nationallicence Chemoradiotherapy nationallicence Mizumachi Takatsugu Department of Otolaryngology-Head and Neck Surgery, Hokkaido University Graduate School of Medicine, Kita 15, Nishi 7, Kita-ku, 060-8638, Sapporo, Japan aut Homma Akihiro Department of Otolaryngology-Head and Neck Surgery, Hokkaido University Graduate School of Medicine, Kita 15, Nishi 7, Kita-ku, 060-8638, Sapporo, Japan aut Kakizaki Tomohiko Department of Otolaryngology-Head and Neck Surgery, Hokkaido University Graduate School of Medicine, Kita 15, Nishi 7, Kita-ku, 060-8638, Sapporo, Japan aut Sakashita Tomohiro Department of Otolaryngology-Head and Neck Surgery, Hokkaido University Graduate School of Medicine, Kita 15, Nishi 7, Kita-ku, 060-8638, Sapporo, Japan aut Kano Satoshi Department of Otolaryngology-Head and Neck Surgery, Hokkaido University Graduate School of Medicine, Kita 15, Nishi 7, Kita-ku, 060-8638, Sapporo, Japan aut Hatakeyama Hiromitsu Department of Otolaryngology-Head and Neck Surgery, Hokkaido University Graduate School of Medicine, Kita 15, Nishi 7, Kita-ku, 060-8638, Sapporo, Japan aut Tsuchiya Kazuhiko Department of Radiation Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan aut Yasuda Koichi Department of Radiation Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan aut Onimaru Rikiya Department of Radiation Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan aut Shirato Hiroki Department of Radiation Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan aut Taguchi Jun Department of Medical Oncology, Hokkaido University Graduate School of Medicine, Sapporo, Japan aut Shimizu Yasushi Department of Medical Oncology, Hokkaido University Graduate School of Medicine, Sapporo, Japan aut Kinoshita Ichiro Department of Medical Oncology, Hokkaido University Graduate School of Medicine, Sapporo, Japan aut Akita Hirotoshi Department of Medical Oncology, Hokkaido University Graduate School of Medicine, Sapporo, Japan aut Fukuda Satoshi Department of Otolaryngology-Head and Neck Surgery, Hokkaido University Graduate School of Medicine, Kita 15, Nishi 7, Kita-ku, 060-8638, Sapporo, Japan aut International Journal of Clinical Oncology Springer Japan 20/3(2015-06-01), 431-437 1341-9625 20:3<431 2015 20 10147 https://doi.org/10.1007/s10147-014-0726-y text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s10147-014-0726-y text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Mizumachi Takatsugu Department of Otolaryngology-Head and Neck Surgery, Hokkaido University Graduate School of Medicine, Kita 15, Nishi 7, Kita-ku, 060-8638, Sapporo, Japan aut NATIONALLICENCE 700 1- Homma Akihiro Department of Otolaryngology-Head and Neck Surgery, Hokkaido University Graduate School of Medicine, Kita 15, Nishi 7, Kita-ku, 060-8638, Sapporo, Japan aut NATIONALLICENCE 700 1- Kakizaki Tomohiko Department of Otolaryngology-Head and Neck Surgery, Hokkaido University Graduate School of Medicine, Kita 15, Nishi 7, Kita-ku, 060-8638, Sapporo, Japan aut NATIONALLICENCE 700 1- Sakashita Tomohiro Department of Otolaryngology-Head and Neck Surgery, Hokkaido University Graduate School of Medicine, Kita 15, Nishi 7, Kita-ku, 060-8638, Sapporo, Japan aut NATIONALLICENCE 700 1- Kano Satoshi Department of Otolaryngology-Head and Neck Surgery, Hokkaido University Graduate School of Medicine, Kita 15, Nishi 7, Kita-ku, 060-8638, Sapporo, Japan aut NATIONALLICENCE 700 1- Hatakeyama Hiromitsu Department of Otolaryngology-Head and Neck Surgery, Hokkaido University Graduate School of Medicine, Kita 15, Nishi 7, Kita-ku, 060-8638, Sapporo, Japan aut NATIONALLICENCE 700 1- Tsuchiya Kazuhiko Department of Radiation Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan aut NATIONALLICENCE 700 1- Yasuda Koichi Department of Radiation Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan aut NATIONALLICENCE 700 1- Onimaru Rikiya Department of Radiation Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan aut NATIONALLICENCE 700 1- Shirato Hiroki Department of Radiation Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan aut NATIONALLICENCE 700 1- Taguchi Jun Department of Medical Oncology, Hokkaido University Graduate School of Medicine, Sapporo, Japan aut NATIONALLICENCE 700 1- Shimizu Yasushi Department of Medical Oncology, Hokkaido University Graduate School of Medicine, Sapporo, Japan aut NATIONALLICENCE 700 1- Kinoshita Ichiro Department of Medical Oncology, Hokkaido University Graduate School of Medicine, Sapporo, Japan aut NATIONALLICENCE 700 1- Akita Hirotoshi Department of Medical Oncology, Hokkaido University Graduate School of Medicine, Sapporo, Japan aut NATIONALLICENCE 700 1- Fukuda Satoshi Department of Otolaryngology-Head and Neck Surgery, Hokkaido University Graduate School of Medicine, Kita 15, Nishi 7, Kita-ku, 060-8638, Sapporo, Japan aut NATIONALLICENCE 773 0- International Journal of Clinical Oncology Springer Japan 20/3(2015-06-01), 431-437 1341-9625 20:3<431 2015 20 10147